多価連鎖球菌・肺炎球菌ワクチンのグローバル市場インサイト・予測（～2028年）

• 英文タイトル：Global Polyvalent Streptococcus Pneumococcal Vaccines Market Insights, Forecast to 2028

• レポートコード：QY2207E10470 • 出版社/出版日：QYResearch / 2022年7月 • レポート形態：英文、PDF、116ページ • 納品方法：Eメール（納期：3日） • 産業分類：医薬品

• 販売価格（消費税別）

Single User	￥725,200 (USD4,900)	▷ お問い合わせ
Multi User	￥1,087,800 (USD7,350)	▷ お問い合わせ
Enterprise License	￥1,450,400 (USD9,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

新型コロナウイルス感染症のパンデミックにより、世界の多価連鎖球菌・肺炎球菌ワクチンの市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx％で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年に多価連鎖球菌・肺炎球菌ワクチンの世界市場のxxx％を占める「9価」タイプは、2028年までにUS$xxxの規模になり、パンデミック後の修正xxx％CAGRで成長すると予測されています。一方、「病院」セグメントは、この予測期間を通じてxxx％のCAGRに変更されます。 中国の多価連鎖球菌・肺炎球菌ワクチンの市場規模は2021年にUS$xxxと分析されており、米国とヨーロッパの多価連鎖球菌・肺炎球菌ワクチン市場規模はそれぞれUS$xxxとUS$xxxです。米国の割合は2021年にxxx％であり、中国とヨーロッパはそれぞれxxx％とxxx％です。中国の割合は2028年にxxx％に達し、対象期間を通じてxxx％のCAGRを記録すると予測されています。日本、韓国、東南アジアはアジアで注目市場であり、今後6年間のCAGRはそれぞれxxx％、xxx％、xxx％になる見通しです。ヨーロッパの多価連鎖球菌・肺炎球菌ワクチン市場については、ドイツは2028年までにUS$xxxに達すると予測されており、予測期間中のCAGRはxxx％になる見通しです。 多価連鎖球菌・肺炎球菌ワクチンのグローバル主要メーカーには、GlaxoSmithKline、LG Chem、Merck、Panacea Biotec、AstraZeneca、Pfizer、Shire、Pnuvax Incorporated、Serum Institute、Shinogi、Shenzhen Kangtai Biological Products、SK Bioscience、Walvax Biotechnology、Eli Lilly、Abera、Sanofi、Genentechなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx％の市場シェアを占めています。 多価連鎖球菌・肺炎球菌ワクチン市場は、種類と用途によって区分されます。世界の多価連鎖球菌・肺炎球菌ワクチン市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年～2028年期間のタイプ別および用途別の販売量、売上、予測に焦点を当てています。 【種類別セグメント】 9価、13価、23価、その他 【用途別セグメント】 病院、地域クリニック、保健所、その他 【掲載地域】 北米：アメリカ、カナダ ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア アジア太平洋：日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア 中南米：メキシコ、ブラジル、アルゼンチン 中東・アフリカ：トルコ、サウジアラビア、UAE 【目次（一部）】 ・調査の範囲 - 多価連鎖球菌・肺炎球菌ワクチン製品概要 - 種類別市場（9価、13価、23価、その他） - 用途別市場（病院、地域クリニック、保健所、その他） - 調査の目的 ・エグゼクティブサマリー - 世界の多価連鎖球菌・肺炎球菌ワクチン販売量予測2017-2028 - 世界の多価連鎖球菌・肺炎球菌ワクチン売上予測2017-2028 - 多価連鎖球菌・肺炎球菌ワクチンの地域別販売量 - 多価連鎖球菌・肺炎球菌ワクチンの地域別売上 - 北米市場 - ヨーロッパ市場 - アジア太平洋市場 - 中南米市場 - 中東・アフリカ市場 ・メーカーの競争状況 - 主要メーカー別多価連鎖球菌・肺炎球菌ワクチン販売量 - 主要メーカー別多価連鎖球菌・肺炎球菌ワクチン売上 - 主要メーカー別多価連鎖球菌・肺炎球菌ワクチン価格 - 競争状況の分析 - 企業M&A動向 ・種類別市場規模（9価、13価、23価、その他） - 多価連鎖球菌・肺炎球菌ワクチンの種類別販売量 - 多価連鎖球菌・肺炎球菌ワクチンの種類別売上 - 多価連鎖球菌・肺炎球菌ワクチンの種類別価格 ・用途別市場規模（病院、地域クリニック、保健所、その他） - 多価連鎖球菌・肺炎球菌ワクチンの用途別販売量 - 多価連鎖球菌・肺炎球菌ワクチンの用途別売上 - 多価連鎖球菌・肺炎球菌ワクチンの用途別価格 ・北米市場 - 北米の多価連鎖球菌・肺炎球菌ワクチン市場規模（種類別、用途別） - 主要国別の多価連鎖球菌・肺炎球菌ワクチン市場規模（アメリカ、カナダ） ・ヨーロッパ市場 - ヨーロッパの多価連鎖球菌・肺炎球菌ワクチン市場規模（種類別、用途別） - 主要国別の多価連鎖球菌・肺炎球菌ワクチン市場規模（ドイツ、フランス、イギリス、イタリア、ロシア） ・アジア太平洋市場 - アジア太平洋の多価連鎖球菌・肺炎球菌ワクチン市場規模（種類別、用途別） - 主要国別の多価連鎖球菌・肺炎球菌ワクチン市場規模（日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア） ・中南米市場 - 中南米の多価連鎖球菌・肺炎球菌ワクチン市場規模（種類別、用途別） - 主要国別の多価連鎖球菌・肺炎球菌ワクチン市場規模（メキシコ、ブラジル、アルゼンチン） ・中東・アフリカ市場 - 中東・アフリカの多価連鎖球菌・肺炎球菌ワクチン市場規模（種類別、用途別） - 主要国別の多価連鎖球菌・肺炎球菌ワクチン市場規模（トルコ、サウジアラビア） ・企業情報 GlaxoSmithKline、LG Chem、Merck、Panacea Biotec、AstraZeneca、Pfizer、Shire、Pnuvax Incorporated、Serum Institute、Shinogi、Shenzhen Kangtai Biological Products、SK Bioscience、Walvax Biotechnology、Eli Lilly、Abera、Sanofi、Genentech ・産業チェーン及び販売チャネル分析 - 多価連鎖球菌・肺炎球菌ワクチンの産業チェーン分析 - 多価連鎖球菌・肺炎球菌ワクチンの原材料 - 多価連鎖球菌・肺炎球菌ワクチンの生産プロセス - 多価連鎖球菌・肺炎球菌ワクチンの販売及びマーケティング - 多価連鎖球菌・肺炎球菌ワクチンの主要顧客 ・マーケットドライバー、機会、課題、リスク要因分析 - 多価連鎖球菌・肺炎球菌ワクチンの産業動向 - 多価連鎖球菌・肺炎球菌ワクチンのマーケットドライバー - 多価連鎖球菌・肺炎球菌ワクチンの課題 - 多価連鎖球菌・肺炎球菌ワクチンの阻害要因 ・主な調査結果

The polyvalent streptococcus pneumoniae vaccine is a vaccine that mainly prevents pneumonia caused by Streptococcus pneumoniae. It contains a variety of serotypes that often cause streptococcus pneumoniae infection. After vaccination, it can effectively reduce the risk of pneumonia infection.
Market Analysis and Insights: Global Polyvalent Streptococcus Pneumococcal Vaccines Market
Due to the COVID-19 pandemic, the global Polyvalent Streptococcus Pneumococcal Vaccines market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, 9-Valent accounting for % of the Polyvalent Streptococcus Pneumococcal Vaccines global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Hospital segment is altered to an % CAGR throughout this forecast period.
China Polyvalent Streptococcus Pneumococcal Vaccines market size is valued at US$ million in 2021, while the US and Europe Polyvalent Streptococcus Pneumococcal Vaccines are US$ million and US$ million, severally. The proportion of the US is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period 2022-2028. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Polyvalent Streptococcus Pneumococcal Vaccines landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period 2022-2028.
The global key manufacturers of Polyvalent Streptococcus Pneumococcal Vaccines include GlaxoSmithKline, LG Chem, Merck, Panacea Biotec, AstraZeneca, Pfizer, Shire, Pnuvax Incorporated and Serum Institute, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
Global Polyvalent Streptococcus Pneumococcal Vaccines Scope and Segment
Polyvalent Streptococcus Pneumococcal Vaccines market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Polyvalent Streptococcus Pneumococcal Vaccines market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
9-Valent
13-Valent
23-Valent
Others
Segment by Application
Hospital
Community Clinics
Public Health Agencies
Others
By Company
GlaxoSmithKline
LG Chem
Merck
Panacea Biotec
AstraZeneca
Pfizer
Shire
Pnuvax Incorporated
Serum Institute
Shinogi
Shenzhen Kangtai Biological Products
SK Bioscience
Walvax Biotechnology
Eli Lilly
Abera
Sanofi
Genentech
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

レポート目次

---

1 Study Coverage
1.1 Polyvalent Streptococcus Pneumococcal Vaccines Product Introduction
1.2 Market by Type
1.2.1 Global Polyvalent Streptococcus Pneumococcal Vaccines Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 9-Valent
1.2.3 13-Valent
1.2.4 23-Valent
1.2.5 Others
1.3 Market by Application
1.3.1 Global Polyvalent Streptococcus Pneumococcal Vaccines Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Hospital
1.3.3 Community Clinics
1.3.4 Public Health Agencies
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Polyvalent Streptococcus Pneumococcal Vaccines Sales Estimates and Forecasts 2017-2028
2.2 Global Polyvalent Streptococcus Pneumococcal Vaccines Revenue Estimates and Forecasts 2017-2028
2.3 Global Polyvalent Streptococcus Pneumococcal Vaccines Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global Polyvalent Streptococcus Pneumococcal Vaccines Sales by Region
2.4.1 Global Polyvalent Streptococcus Pneumococcal Vaccines Sales by Region (2017-2022)
2.4.2 Global Sales Polyvalent Streptococcus Pneumococcal Vaccines by Region (2023-2028)
2.5 Global Polyvalent Streptococcus Pneumococcal Vaccines Revenue by Region
2.5.1 Global Polyvalent Streptococcus Pneumococcal Vaccines Revenue by Region (2017-2022)
2.5.2 Global Polyvalent Streptococcus Pneumococcal Vaccines Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Polyvalent Streptococcus Pneumococcal Vaccines Sales by Manufacturers
3.1.1 Global Top Polyvalent Streptococcus Pneumococcal Vaccines Manufacturers by Sales (2017-2022)
3.1.2 Global Polyvalent Streptococcus Pneumococcal Vaccines Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Polyvalent Streptococcus Pneumococcal Vaccines in 2021
3.2 Global Polyvalent Streptococcus Pneumococcal Vaccines Revenue by Manufacturers
3.2.1 Global Polyvalent Streptococcus Pneumococcal Vaccines Revenue by Manufacturers (2017-2022)
3.2.2 Global Polyvalent Streptococcus Pneumococcal Vaccines Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by Polyvalent Streptococcus Pneumococcal Vaccines Revenue in 2021
3.3 Global Polyvalent Streptococcus Pneumococcal Vaccines Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Polyvalent Streptococcus Pneumococcal Vaccines Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Polyvalent Streptococcus Pneumococcal Vaccines Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Polyvalent Streptococcus Pneumococcal Vaccines Sales by Type
4.1.1 Global Polyvalent Streptococcus Pneumococcal Vaccines Historical Sales by Type (2017-2022)
4.1.2 Global Polyvalent Streptococcus Pneumococcal Vaccines Forecasted Sales by Type (2023-2028)
4.1.3 Global Polyvalent Streptococcus Pneumococcal Vaccines Sales Market Share by Type (2017-2028)
4.2 Global Polyvalent Streptococcus Pneumococcal Vaccines Revenue by Type
4.2.1 Global Polyvalent Streptococcus Pneumococcal Vaccines Historical Revenue by Type (2017-2022)
4.2.2 Global Polyvalent Streptococcus Pneumococcal Vaccines Forecasted Revenue by Type (2023-2028)
4.2.3 Global Polyvalent Streptococcus Pneumococcal Vaccines Revenue Market Share by Type (2017-2028)
4.3 Global Polyvalent Streptococcus Pneumococcal Vaccines Price by Type
4.3.1 Global Polyvalent Streptococcus Pneumococcal Vaccines Price by Type (2017-2022)
4.3.2 Global Polyvalent Streptococcus Pneumococcal Vaccines Price Forecast by Type (2023-2028)
5 Market Size by Application
5.1 Global Polyvalent Streptococcus Pneumococcal Vaccines Sales by Application
5.1.1 Global Polyvalent Streptococcus Pneumococcal Vaccines Historical Sales by Application (2017-2022)
5.1.2 Global Polyvalent Streptococcus Pneumococcal Vaccines Forecasted Sales by Application (2023-2028)
5.1.3 Global Polyvalent Streptococcus Pneumococcal Vaccines Sales Market Share by Application (2017-2028)
5.2 Global Polyvalent Streptococcus Pneumococcal Vaccines Revenue by Application
5.2.1 Global Polyvalent Streptococcus Pneumococcal Vaccines Historical Revenue by Application (2017-2022)
5.2.2 Global Polyvalent Streptococcus Pneumococcal Vaccines Forecasted Revenue by Application (2023-2028)
5.2.3 Global Polyvalent Streptococcus Pneumococcal Vaccines Revenue Market Share by Application (2017-2028)
5.3 Global Polyvalent Streptococcus Pneumococcal Vaccines Price by Application
5.3.1 Global Polyvalent Streptococcus Pneumococcal Vaccines Price by Application (2017-2022)
5.3.2 Global Polyvalent Streptococcus Pneumococcal Vaccines Price Forecast by Application (2023-2028)
6 North America
6.1 North America Polyvalent Streptococcus Pneumococcal Vaccines Market Size by Type
6.1.1 North America Polyvalent Streptococcus Pneumococcal Vaccines Sales by Type (2017-2028)
6.1.2 North America Polyvalent Streptococcus Pneumococcal Vaccines Revenue by Type (2017-2028)
6.2 North America Polyvalent Streptococcus Pneumococcal Vaccines Market Size by Application
6.2.1 North America Polyvalent Streptococcus Pneumococcal Vaccines Sales by Application (2017-2028)
6.2.2 North America Polyvalent Streptococcus Pneumococcal Vaccines Revenue by Application (2017-2028)
6.3 North America Polyvalent Streptococcus Pneumococcal Vaccines Market Size by Country
6.3.1 North America Polyvalent Streptococcus Pneumococcal Vaccines Sales by Country (2017-2028)
6.3.2 North America Polyvalent Streptococcus Pneumococcal Vaccines Revenue by Country (2017-2028)
6.3.3 United States
6.3.4 Canada
7 Europe
7.1 Europe Polyvalent Streptococcus Pneumococcal Vaccines Market Size by Type
7.1.1 Europe Polyvalent Streptococcus Pneumococcal Vaccines Sales by Type (2017-2028)
7.1.2 Europe Polyvalent Streptococcus Pneumococcal Vaccines Revenue by Type (2017-2028)
7.2 Europe Polyvalent Streptococcus Pneumococcal Vaccines Market Size by Application
7.2.1 Europe Polyvalent Streptococcus Pneumococcal Vaccines Sales by Application (2017-2028)
7.2.2 Europe Polyvalent Streptococcus Pneumococcal Vaccines Revenue by Application (2017-2028)
7.3 Europe Polyvalent Streptococcus Pneumococcal Vaccines Market Size by Country
7.3.1 Europe Polyvalent Streptococcus Pneumococcal Vaccines Sales by Country (2017-2028)
7.3.2 Europe Polyvalent Streptococcus Pneumococcal Vaccines Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Polyvalent Streptococcus Pneumococcal Vaccines Market Size by Type
8.1.1 Asia Pacific Polyvalent Streptococcus Pneumococcal Vaccines Sales by Type (2017-2028)
8.1.2 Asia Pacific Polyvalent Streptococcus Pneumococcal Vaccines Revenue by Type (2017-2028)
8.2 Asia Pacific Polyvalent Streptococcus Pneumococcal Vaccines Market Size by Application
8.2.1 Asia Pacific Polyvalent Streptococcus Pneumococcal Vaccines Sales by Application (2017-2028)
8.2.2 Asia Pacific Polyvalent Streptococcus Pneumococcal Vaccines Revenue by Application (2017-2028)
8.3 Asia Pacific Polyvalent Streptococcus Pneumococcal Vaccines Market Size by Region
8.3.1 Asia Pacific Polyvalent Streptococcus Pneumococcal Vaccines Sales by Region (2017-2028)
8.3.2 Asia Pacific Polyvalent Streptococcus Pneumococcal Vaccines Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 China Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
9 Latin America
9.1 Latin America Polyvalent Streptococcus Pneumococcal Vaccines Market Size by Type
9.1.1 Latin America Polyvalent Streptococcus Pneumococcal Vaccines Sales by Type (2017-2028)
9.1.2 Latin America Polyvalent Streptococcus Pneumococcal Vaccines Revenue by Type (2017-2028)
9.2 Latin America Polyvalent Streptococcus Pneumococcal Vaccines Market Size by Application
9.2.1 Latin America Polyvalent Streptococcus Pneumococcal Vaccines Sales by Application (2017-2028)
9.2.2 Latin America Polyvalent Streptococcus Pneumococcal Vaccines Revenue by Application (2017-2028)
9.3 Latin America Polyvalent Streptococcus Pneumococcal Vaccines Market Size by Country
9.3.1 Latin America Polyvalent Streptococcus Pneumococcal Vaccines Sales by Country (2017-2028)
9.3.2 Latin America Polyvalent Streptococcus Pneumococcal Vaccines Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Polyvalent Streptococcus Pneumococcal Vaccines Market Size by Type
10.1.1 Middle East and Africa Polyvalent Streptococcus Pneumococcal Vaccines Sales by Type (2017-2028)
10.1.2 Middle East and Africa Polyvalent Streptococcus Pneumococcal Vaccines Revenue by Type (2017-2028)
10.2 Middle East and Africa Polyvalent Streptococcus Pneumococcal Vaccines Market Size by Application
10.2.1 Middle East and Africa Polyvalent Streptococcus Pneumococcal Vaccines Sales by Application (2017-2028)
10.2.2 Middle East and Africa Polyvalent Streptococcus Pneumococcal Vaccines Revenue by Application (2017-2028)
10.3 Middle East and Africa Polyvalent Streptococcus Pneumococcal Vaccines Market Size by Country
10.3.1 Middle East and Africa Polyvalent Streptococcus Pneumococcal Vaccines Sales by Country (2017-2028)
10.3.2 Middle East and Africa Polyvalent Streptococcus Pneumococcal Vaccines Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 GlaxoSmithKline
11.1.1 GlaxoSmithKline Corporation Information
11.1.2 GlaxoSmithKline Overview
11.1.3 GlaxoSmithKline Polyvalent Streptococcus Pneumococcal Vaccines Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 GlaxoSmithKline Polyvalent Streptococcus Pneumococcal Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 GlaxoSmithKline Recent Developments
11.2 LG Chem
11.2.1 LG Chem Corporation Information
11.2.2 LG Chem Overview
11.2.3 LG Chem Polyvalent Streptococcus Pneumococcal Vaccines Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 LG Chem Polyvalent Streptococcus Pneumococcal Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 LG Chem Recent Developments
11.3 Merck
11.3.1 Merck Corporation Information
11.3.2 Merck Overview
11.3.3 Merck Polyvalent Streptococcus Pneumococcal Vaccines Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 Merck Polyvalent Streptococcus Pneumococcal Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Merck Recent Developments
11.4 Panacea Biotec
11.4.1 Panacea Biotec Corporation Information
11.4.2 Panacea Biotec Overview
11.4.3 Panacea Biotec Polyvalent Streptococcus Pneumococcal Vaccines Sales, Price, Revenue and Gross Margin (2017-2022)
11.4.4 Panacea Biotec Polyvalent Streptococcus Pneumococcal Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Panacea Biotec Recent Developments
11.5 AstraZeneca
11.5.1 AstraZeneca Corporation Information
11.5.2 AstraZeneca Overview
11.5.3 AstraZeneca Polyvalent Streptococcus Pneumococcal Vaccines Sales, Price, Revenue and Gross Margin (2017-2022)
11.5.4 AstraZeneca Polyvalent Streptococcus Pneumococcal Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 AstraZeneca Recent Developments
11.6 Pfizer
11.6.1 Pfizer Corporation Information
11.6.2 Pfizer Overview
11.6.3 Pfizer Polyvalent Streptococcus Pneumococcal Vaccines Sales, Price, Revenue and Gross Margin (2017-2022)
11.6.4 Pfizer Polyvalent Streptococcus Pneumococcal Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Pfizer Recent Developments
11.7 Shire
11.7.1 Shire Corporation Information
11.7.2 Shire Overview
11.7.3 Shire Polyvalent Streptococcus Pneumococcal Vaccines Sales, Price, Revenue and Gross Margin (2017-2022)
11.7.4 Shire Polyvalent Streptococcus Pneumococcal Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Shire Recent Developments
11.8 Pnuvax Incorporated
11.8.1 Pnuvax Incorporated Corporation Information
11.8.2 Pnuvax Incorporated Overview
11.8.3 Pnuvax Incorporated Polyvalent Streptococcus Pneumococcal Vaccines Sales, Price, Revenue and Gross Margin (2017-2022)
11.8.4 Pnuvax Incorporated Polyvalent Streptococcus Pneumococcal Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Pnuvax Incorporated Recent Developments
11.9 Serum Institute
11.9.1 Serum Institute Corporation Information
11.9.2 Serum Institute Overview
11.9.3 Serum Institute Polyvalent Streptococcus Pneumococcal Vaccines Sales, Price, Revenue and Gross Margin (2017-2022)
11.9.4 Serum Institute Polyvalent Streptococcus Pneumococcal Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 Serum Institute Recent Developments
11.10 Shinogi
11.10.1 Shinogi Corporation Information
11.10.2 Shinogi Overview
11.10.3 Shinogi Polyvalent Streptococcus Pneumococcal Vaccines Sales, Price, Revenue and Gross Margin (2017-2022)
11.10.4 Shinogi Polyvalent Streptococcus Pneumococcal Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 Shinogi Recent Developments
11.11 Shenzhen Kangtai Biological Products
11.11.1 Shenzhen Kangtai Biological Products Corporation Information
11.11.2 Shenzhen Kangtai Biological Products Overview
11.11.3 Shenzhen Kangtai Biological Products Polyvalent Streptococcus Pneumococcal Vaccines Sales, Price, Revenue and Gross Margin (2017-2022)
11.11.4 Shenzhen Kangtai Biological Products Polyvalent Streptococcus Pneumococcal Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
11.11.5 Shenzhen Kangtai Biological Products Recent Developments
11.12 SK Bioscience
11.12.1 SK Bioscience Corporation Information
11.12.2 SK Bioscience Overview
11.12.3 SK Bioscience Polyvalent Streptococcus Pneumococcal Vaccines Sales, Price, Revenue and Gross Margin (2017-2022)
11.12.4 SK Bioscience Polyvalent Streptococcus Pneumococcal Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
11.12.5 SK Bioscience Recent Developments
11.13 Walvax Biotechnology
11.13.1 Walvax Biotechnology Corporation Information
11.13.2 Walvax Biotechnology Overview
11.13.3 Walvax Biotechnology Polyvalent Streptococcus Pneumococcal Vaccines Sales, Price, Revenue and Gross Margin (2017-2022)
11.13.4 Walvax Biotechnology Polyvalent Streptococcus Pneumococcal Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
11.13.5 Walvax Biotechnology Recent Developments
11.14 Eli Lilly
11.14.1 Eli Lilly Corporation Information
11.14.2 Eli Lilly Overview
11.14.3 Eli Lilly Polyvalent Streptococcus Pneumococcal Vaccines Sales, Price, Revenue and Gross Margin (2017-2022)
11.14.4 Eli Lilly Polyvalent Streptococcus Pneumococcal Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
11.14.5 Eli Lilly Recent Developments
11.15 Abera
11.15.1 Abera Corporation Information
11.15.2 Abera Overview
11.15.3 Abera Polyvalent Streptococcus Pneumococcal Vaccines Sales, Price, Revenue and Gross Margin (2017-2022)
11.15.4 Abera Polyvalent Streptococcus Pneumococcal Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
11.15.5 Abera Recent Developments
11.16 Sanofi
11.16.1 Sanofi Corporation Information
11.16.2 Sanofi Overview
11.16.3 Sanofi Polyvalent Streptococcus Pneumococcal Vaccines Sales, Price, Revenue and Gross Margin (2017-2022)
11.16.4 Sanofi Polyvalent Streptococcus Pneumococcal Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
11.16.5 Sanofi Recent Developments
11.17 Genentech
11.17.1 Genentech Corporation Information
11.17.2 Genentech Overview
11.17.3 Genentech Polyvalent Streptococcus Pneumococcal Vaccines Sales, Price, Revenue and Gross Margin (2017-2022)
11.17.4 Genentech Polyvalent Streptococcus Pneumococcal Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
11.17.5 Genentech Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Polyvalent Streptococcus Pneumococcal Vaccines Industry Chain Analysis
12.2 Polyvalent Streptococcus Pneumococcal Vaccines Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Polyvalent Streptococcus Pneumococcal Vaccines Production Mode & Process
12.4 Polyvalent Streptococcus Pneumococcal Vaccines Sales and Marketing
12.4.1 Polyvalent Streptococcus Pneumococcal Vaccines Sales Channels
12.4.2 Polyvalent Streptococcus Pneumococcal Vaccines Distributors
12.5 Polyvalent Streptococcus Pneumococcal Vaccines Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Polyvalent Streptococcus Pneumococcal Vaccines Industry Trends
13.2 Polyvalent Streptococcus Pneumococcal Vaccines Market Drivers
13.3 Polyvalent Streptococcus Pneumococcal Vaccines Market Challenges
13.4 Polyvalent Streptococcus Pneumococcal Vaccines Market Restraints
14 Key Findings in The Global Polyvalent Streptococcus Pneumococcal Vaccines Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Tables
Table 1. Global Polyvalent Streptococcus Pneumococcal Vaccines Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 (US$ Million)
Table 2. Major Manufacturers of 9-Valent
Table 3. Major Manufacturers of 13-Valent
Table 4. Major Manufacturers of 23-Valent
Table 5. Major Manufacturers of Others
Table 6. Global Polyvalent Streptococcus Pneumococcal Vaccines Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 (US$ Million)
Table 7. Global Polyvalent Streptococcus Pneumococcal Vaccines Revenue by Region: 2017 VS 2021 VS 2028 (US$ Million)
Table 8. Global Polyvalent Streptococcus Pneumococcal Vaccines Sales by Region (2017-2022) & (K Units)
Table 9. Global Polyvalent Streptococcus Pneumococcal Vaccines Sales Market Share by Region (2017-2022)
Table 10. Global Polyvalent Streptococcus Pneumococcal Vaccines Sales by Region (2023-2028) & (K Units)
Table 11. Global Polyvalent Streptococcus Pneumococcal Vaccines Sales Market Share by Region (2023-2028)
Table 12. Global Polyvalent Streptococcus Pneumococcal Vaccines Revenue by Region (2017-2022) & (US$ Million)
Table 13. Global Polyvalent Streptococcus Pneumococcal Vaccines Revenue Market Share by Region (2017-2022)
Table 14. Global Polyvalent Streptococcus Pneumococcal Vaccines Revenue by Region (2023-2028) & (US$ Million)
Table 15. Global Polyvalent Streptococcus Pneumococcal Vaccines Revenue Market Share by Region (2023-2028)
Table 16. Global Polyvalent Streptococcus Pneumococcal Vaccines Sales by Manufacturers (2017-2022) & (K Units)
Table 17. Global Polyvalent Streptococcus Pneumococcal Vaccines Sales Share by Manufacturers (2017-2022)
Table 18. Global Polyvalent Streptococcus Pneumococcal Vaccines Revenue by Manufacturers (2017-2022) & (US$ Million)
Table 19. Global Polyvalent Streptococcus Pneumococcal Vaccines Revenue Share by Manufacturers (2017-2022)
Table 20. Polyvalent Streptococcus Pneumococcal Vaccines Price by Manufacturers (2017-2022) &(US$/Unit)
Table 21. Global Polyvalent Streptococcus Pneumococcal Vaccines Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 22. Global Polyvalent Streptococcus Pneumococcal Vaccines by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Polyvalent Streptococcus Pneumococcal Vaccines as of 2021)
Table 23. Polyvalent Streptococcus Pneumococcal Vaccines Manufacturing Base Distribution and Headquarters
Table 24. Manufacturers Polyvalent Streptococcus Pneumococcal Vaccines Product Offered
Table 25. Date of Manufacturers Enter into Polyvalent Streptococcus Pneumococcal Vaccines Market
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Polyvalent Streptococcus Pneumococcal Vaccines Sales by Type (2017-2022) & (K Units)
Table 28. Global Polyvalent Streptococcus Pneumococcal Vaccines Sales by Type (2023-2028) & (K Units)
Table 29. Global Polyvalent Streptococcus Pneumococcal Vaccines Sales Share by Type (2017-2022)
Table 30. Global Polyvalent Streptococcus Pneumococcal Vaccines Sales Share by Type (2023-2028)
Table 31. Global Polyvalent Streptococcus Pneumococcal Vaccines Revenue by Type (2017-2022) & (US$ Million)
Table 32. Global Polyvalent Streptococcus Pneumococcal Vaccines Revenue by Type (2023-2028) & (US$ Million)
Table 33. Global Polyvalent Streptococcus Pneumococcal Vaccines Revenue Share by Type (2017-2022)
Table 34. Global Polyvalent Streptococcus Pneumococcal Vaccines Revenue Share by Type (2023-2028)
Table 35. Polyvalent Streptococcus Pneumococcal Vaccines Price by Type (2017-2022) & (US$/Unit)
Table 36. Global Polyvalent Streptococcus Pneumococcal Vaccines Price Forecast by Type (2023-2028) & (US$/Unit)
Table 37. Global Polyvalent Streptococcus Pneumococcal Vaccines Sales by Application (2017-2022) & (K Units)
Table 38. Global Polyvalent Streptococcus Pneumococcal Vaccines Sales by Application (2023-2028) & (K Units)
Table 39. Global Polyvalent Streptococcus Pneumococcal Vaccines Sales Share by Application (2017-2022)
Table 40. Global Polyvalent Streptococcus Pneumococcal Vaccines Sales Share by Application (2023-2028)
Table 41. Global Polyvalent Streptococcus Pneumococcal Vaccines Revenue by Application (2017-2022) & (US$ Million)
Table 42. Global Polyvalent Streptococcus Pneumococcal Vaccines Revenue by Application (2023-2028) & (US$ Million)
Table 43. Global Polyvalent Streptococcus Pneumococcal Vaccines Revenue Share by Application (2017-2022)
Table 44. Global Polyvalent Streptococcus Pneumococcal Vaccines Revenue Share by Application (2023-2028)
Table 45. Polyvalent Streptococcus Pneumococcal Vaccines Price by Application (2017-2022) & (US$/Unit)
Table 46. Global Polyvalent Streptococcus Pneumococcal Vaccines Price Forecast by Application (2023-2028) & (US$/Unit)
Table 47. North America Polyvalent Streptococcus Pneumococcal Vaccines Sales by Type (2017-2022) & (K Units)
Table 48. North America Polyvalent Streptococcus Pneumococcal Vaccines Sales by Type (2023-2028) & (K Units)
Table 49. North America Polyvalent Streptococcus Pneumococcal Vaccines Revenue by Type (2017-2022) & (US$ Million)
Table 50. North America Polyvalent Streptococcus Pneumococcal Vaccines Revenue by Type (2023-2028) & (US$ Million)
Table 51. North America Polyvalent Streptococcus Pneumococcal Vaccines Sales by Application (2017-2022) & (K Units)
Table 52. North America Polyvalent Streptococcus Pneumococcal Vaccines Sales by Application (2023-2028) & (K Units)
Table 53. North America Polyvalent Streptococcus Pneumococcal Vaccines Revenue by Application (2017-2022) & (US$ Million)
Table 54. North America Polyvalent Streptococcus Pneumococcal Vaccines Revenue by Application (2023-2028) & (US$ Million)
Table 55. North America Polyvalent Streptococcus Pneumococcal Vaccines Sales by Country (2017-2022) & (K Units)
Table 56. North America Polyvalent Streptococcus Pneumococcal Vaccines Sales by Country (2023-2028) & (K Units)
Table 57. North America Polyvalent Streptococcus Pneumococcal Vaccines Revenue by Country (2017-2022) & (US$ Million)
Table 58. North America Polyvalent Streptococcus Pneumococcal Vaccines Revenue by Country (2023-2028) & (US$ Million)
Table 59. Europe Polyvalent Streptococcus Pneumococcal Vaccines Sales by Type (2017-2022) & (K Units)
Table 60. Europe Polyvalent Streptococcus Pneumococcal Vaccines Sales by Type (2023-2028) & (K Units)
Table 61. Europe Polyvalent Streptococcus Pneumococcal Vaccines Revenue by Type (2017-2022) & (US$ Million)
Table 62. Europe Polyvalent Streptococcus Pneumococcal Vaccines Revenue by Type (2023-2028) & (US$ Million)
Table 63. Europe Polyvalent Streptococcus Pneumococcal Vaccines Sales by Application (2017-2022) & (K Units)
Table 64. Europe Polyvalent Streptococcus Pneumococcal Vaccines Sales by Application (2023-2028) & (K Units)
Table 65. Europe Polyvalent Streptococcus Pneumococcal Vaccines Revenue by Application (2017-2022) & (US$ Million)
Table 66. Europe Polyvalent Streptococcus Pneumococcal Vaccines Revenue by Application (2023-2028) & (US$ Million)
Table 67. Europe Polyvalent Streptococcus Pneumococcal Vaccines Sales by Country (2017-2022) & (K Units)
Table 68. Europe Polyvalent Streptococcus Pneumococcal Vaccines Sales by Country (2023-2028) & (K Units)
Table 69. Europe Polyvalent Streptococcus Pneumococcal Vaccines Revenue by Country (2017-2022) & (US$ Million)
Table 70. Europe Polyvalent Streptococcus Pneumococcal Vaccines Revenue by Country (2023-2028) & (US$ Million)
Table 71. Asia Pacific Polyvalent Streptococcus Pneumococcal Vaccines Sales by Type (2017-2022) & (K Units)
Table 72. Asia Pacific Polyvalent Streptococcus Pneumococcal Vaccines Sales by Type (2023-2028) & (K Units)
Table 73. Asia Pacific Polyvalent Streptococcus Pneumococcal Vaccines Revenue by Type (2017-2022) & (US$ Million)
Table 74. Asia Pacific Polyvalent Streptococcus Pneumococcal Vaccines Revenue by Type (2023-2028) & (US$ Million)
Table 75. Asia Pacific Polyvalent Streptococcus Pneumococcal Vaccines Sales by Application (2017-2022) & (K Units)
Table 76. Asia Pacific Polyvalent Streptococcus Pneumococcal Vaccines Sales by Application (2023-2028) & (K Units)
Table 77. Asia Pacific Polyvalent Streptococcus Pneumococcal Vaccines Revenue by Application (2017-2022) & (US$ Million)
Table 78. Asia Pacific Polyvalent Streptococcus Pneumococcal Vaccines Revenue by Application (2023-2028) & (US$ Million)
Table 79. Asia Pacific Polyvalent Streptococcus Pneumococcal Vaccines Sales by Region (2017-2022) & (K Units)
Table 80. Asia Pacific Polyvalent Streptococcus Pneumococcal Vaccines Sales by Region (2023-2028) & (K Units)
Table 81. Asia Pacific Polyvalent Streptococcus Pneumococcal Vaccines Revenue by Region (2017-2022) & (US$ Million)
Table 82. Asia Pacific Polyvalent Streptococcus Pneumococcal Vaccines Revenue by Region (2023-2028) & (US$ Million)
Table 83. Latin America Polyvalent Streptococcus Pneumococcal Vaccines Sales by Type (2017-2022) & (K Units)
Table 84. Latin America Polyvalent Streptococcus Pneumococcal Vaccines Sales by Type (2023-2028) & (K Units)
Table 85. Latin America Polyvalent Streptococcus Pneumococcal Vaccines Revenue by Type (2017-2022) & (US$ Million)
Table 86. Latin America Polyvalent Streptococcus Pneumococcal Vaccines Revenue by Type (2023-2028) & (US$ Million)
Table 87. Latin America Polyvalent Streptococcus Pneumococcal Vaccines Sales by Application (2017-2022) & (K Units)
Table 88. Latin America Polyvalent Streptococcus Pneumococcal Vaccines Sales by Application (2023-2028) & (K Units)
Table 89. Latin America Polyvalent Streptococcus Pneumococcal Vaccines Revenue by Application (2017-2022) & (US$ Million)
Table 90. Latin America Polyvalent Streptococcus Pneumococcal Vaccines Revenue by Application (2023-2028) & (US$ Million)
Table 91. Latin America Polyvalent Streptococcus Pneumococcal Vaccines Sales by Country (2017-2022) & (K Units)
Table 92. Latin America Polyvalent Streptococcus Pneumococcal Vaccines Sales by Country (2023-2028) & (K Units)
Table 93. Latin America Polyvalent Streptococcus Pneumococcal Vaccines Revenue by Country (2017-2022) & (US$ Million)
Table 94. Latin America Polyvalent Streptococcus Pneumococcal Vaccines Revenue by Country (2023-2028) & (US$ Million)
Table 95. Middle East and Africa Polyvalent Streptococcus Pneumococcal Vaccines Sales by Type (2017-2022) & (K Units)
Table 96. Middle East and Africa Polyvalent Streptococcus Pneumococcal Vaccines Sales by Type (2023-2028) & (K Units)
Table 97. Middle East and Africa Polyvalent Streptococcus Pneumococcal Vaccines Revenue by Type (2017-2022) & (US$ Million)
Table 98. Middle East and Africa Polyvalent Streptococcus Pneumococcal Vaccines Revenue by Type (2023-2028) & (US$ Million)
Table 99. Middle East and Africa Polyvalent Streptococcus Pneumococcal Vaccines Sales by Application (2017-2022) & (K Units)
Table 100. Middle East and Africa Polyvalent Streptococcus Pneumococcal Vaccines Sales by Application (2023-2028) & (K Units)
Table 101. Middle East and Africa Polyvalent Streptococcus Pneumococcal Vaccines Revenue by Application (2017-2022) & (US$ Million)
Table 102. Middle East and Africa Polyvalent Streptococcus Pneumococcal Vaccines Revenue by Application (2023-2028) & (US$ Million)
Table 103. Middle East and Africa Polyvalent Streptococcus Pneumococcal Vaccines Sales by Country (2017-2022) & (K Units)
Table 104. Middle East and Africa Polyvalent Streptococcus Pneumococcal Vaccines Sales by Country (2023-2028) & (K Units)
Table 105. Middle East and Africa Polyvalent Streptococcus Pneumococcal Vaccines Revenue by Country (2017-2022) & (US$ Million)
Table 106. Middle East and Africa Polyvalent Streptococcus Pneumococcal Vaccines Revenue by Country (2023-2028) & (US$ Million)
Table 107. GlaxoSmithKline Corporation Information
Table 108. GlaxoSmithKline Description and Major Businesses
Table 109. GlaxoSmithKline Polyvalent Streptococcus Pneumococcal Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 110. GlaxoSmithKline Polyvalent Streptococcus Pneumococcal Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
Table 111. GlaxoSmithKline Recent Developments
Table 112. LG Chem Corporation Information
Table 113. LG Chem Description and Major Businesses
Table 114. LG Chem Polyvalent Streptococcus Pneumococcal Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 115. LG Chem Polyvalent Streptococcus Pneumococcal Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
Table 116. LG Chem Recent Developments
Table 117. Merck Corporation Information
Table 118. Merck Description and Major Businesses
Table 119. Merck Polyvalent Streptococcus Pneumococcal Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 120. Merck Polyvalent Streptococcus Pneumococcal Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
Table 121. Merck Recent Developments
Table 122. Panacea Biotec Corporation Information
Table 123. Panacea Biotec Description and Major Businesses
Table 124. Panacea Biotec Polyvalent Streptococcus Pneumococcal Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 125. Panacea Biotec Polyvalent Streptococcus Pneumococcal Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
Table 126. Panacea Biotec Recent Developments
Table 127. AstraZeneca Corporation Information
Table 128. AstraZeneca Description and Major Businesses
Table 129. AstraZeneca Polyvalent Streptococcus Pneumococcal Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 130. AstraZeneca Polyvalent Streptococcus Pneumococcal Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
Table 131. AstraZeneca Recent Developments
Table 132. Pfizer Corporation Information
Table 133. Pfizer Description and Major Businesses
Table 134. Pfizer Polyvalent Streptococcus Pneumococcal Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 135. Pfizer Polyvalent Streptococcus Pneumococcal Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
Table 136. Pfizer Recent Developments
Table 137. Shire Corporation Information
Table 138. Shire Description and Major Businesses
Table 139. Shire Polyvalent Streptococcus Pneumococcal Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 140. Shire Polyvalent Streptococcus Pneumococcal Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
Table 141. Shire Recent Developments
Table 142. Pnuvax Incorporated Corporation Information
Table 143. Pnuvax Incorporated Description and Major Businesses
Table 144. Pnuvax Incorporated Polyvalent Streptococcus Pneumococcal Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 145. Pnuvax Incorporated Polyvalent Streptococcus Pneumococcal Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
Table 146. Pnuvax Incorporated Recent Developments
Table 147. Serum Institute Corporation Information
Table 148. Serum Institute Description and Major Businesses
Table 149. Serum Institute Polyvalent Streptococcus Pneumococcal Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 150. Serum Institute Polyvalent Streptococcus Pneumococcal Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
Table 151. Serum Institute Recent Developments
Table 152. Shinogi Corporation Information
Table 153. Shinogi Description and Major Businesses
Table 154. Shinogi Polyvalent Streptococcus Pneumococcal Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 155. Shinogi Polyvalent Streptococcus Pneumococcal Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
Table 156. Shinogi Recent Developments
Table 157. Shenzhen Kangtai Biological Products Corporation Information
Table 158. Shenzhen Kangtai Biological Products Description and Major Businesses
Table 159. Shenzhen Kangtai Biological Products Polyvalent Streptococcus Pneumococcal Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 160. Shenzhen Kangtai Biological Products Polyvalent Streptococcus Pneumococcal Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
Table 161. Shenzhen Kangtai Biological Products Recent Developments
Table 162. SK Bioscience Corporation Information
Table 163. SK Bioscience Description and Major Businesses
Table 164. SK Bioscience Polyvalent Streptococcus Pneumococcal Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 165. SK Bioscience Polyvalent Streptococcus Pneumococcal Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
Table 166. SK Bioscience Recent Developments
Table 167. Walvax Biotechnology Corporation Information
Table 168. Walvax Biotechnology Description and Major Businesses
Table 169. Walvax Biotechnology Polyvalent Streptococcus Pneumococcal Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 170. Walvax Biotechnology Polyvalent Streptococcus Pneumococcal Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
Table 171. Walvax Biotechnology Recent Developments
Table 172. Eli Lilly Corporation Information
Table 173. Eli Lilly Description and Major Businesses
Table 174. Eli Lilly Polyvalent Streptococcus Pneumococcal Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 175. Eli Lilly Polyvalent Streptococcus Pneumococcal Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
Table 176. Eli Lilly Recent Developments
Table 177. Abera Corporation Information
Table 178. Abera Description and Major Businesses
Table 179. Abera Polyvalent Streptococcus Pneumococcal Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 180. Abera Polyvalent Streptococcus Pneumococcal Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
Table 181. Abera Recent Developments
Table 182. Sanofi Corporation Information
Table 183. Sanofi Description and Major Businesses
Table 184. Sanofi Polyvalent Streptococcus Pneumococcal Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 185. Sanofi Polyvalent Streptococcus Pneumococcal Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
Table 186. Sanofi Recent Developments
Table 187. Genentech Corporation Information
Table 188. Genentech Description and Major Businesses
Table 189. Genentech Polyvalent Streptococcus Pneumococcal Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 190. Genentech Polyvalent Streptococcus Pneumococcal Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
Table 191. Genentech Recent Developments
Table 192. Key Raw Materials Lists
Table 193. Raw Materials Key Suppliers Lists
Table 194. Polyvalent Streptococcus Pneumococcal Vaccines Distributors List
Table 195. Polyvalent Streptococcus Pneumococcal Vaccines Customers List
Table 196. Polyvalent Streptococcus Pneumococcal Vaccines Market Trends
Table 197. Polyvalent Streptococcus Pneumococcal Vaccines Market Drivers
Table 198. Polyvalent Streptococcus Pneumococcal Vaccines Market Challenges
Table 199. Polyvalent Streptococcus Pneumococcal Vaccines Market Restraints
Table 200. Research Programs/Design for This Report
Table 201. Key Data Information from Secondary Sources
Table 202. Key Data Information from Primary Sources
List of Figures
Figure 1. Polyvalent Streptococcus Pneumococcal Vaccines Product Picture
Figure 3. Global Polyvalent Streptococcus Pneumococcal Vaccines Market Share by Type in 2021 & 2028
Figure 3. 9-Valent Product Picture
Figure 4. 13-Valent Product Picture
Figure 5. 23-Valent Product Picture
Figure 6. Others Product Picture
Figure 7. Global Polyvalent Streptococcus Pneumococcal Vaccines Market Share by Application in 2021 & 2028
Figure 8. Hospital
Figure 9. Community Clinics
Figure 10. Public Health Agencies
Figure 11. Others
Figure 12. Polyvalent Streptococcus Pneumococcal Vaccines Report Years Considered
Figure 13. Global Polyvalent Streptococcus Pneumococcal Vaccines Sales 2017-2028 (K Units)
Figure 14. Global Polyvalent Streptococcus Pneumococcal Vaccines Revenue, (US$ Million), 2017 VS 2021 VS 2028
Figure 15. Global Polyvalent Streptococcus Pneumococcal Vaccines Revenue 2017-2028 (US$ Million)
Figure 16. Global Polyvalent Streptococcus Pneumococcal Vaccines Revenue Market Share by Region in Percentage: 2021 Versus 2028
Figure 17. Global Polyvalent Streptococcus Pneumococcal Vaccines Sales Market Share by Region (2017-2022)
Figure 18. Global Polyvalent Streptococcus Pneumococcal Vaccines Sales Market Share by Region (2023-2028)
Figure 19. North America Polyvalent Streptococcus Pneumococcal Vaccines Sales YoY (2017-2028) & (K Units)
Figure 20. North America Polyvalent Streptococcus Pneumococcal Vaccines Revenue YoY (2017-2028) & (US$ Million)
Figure 21. Europe Polyvalent Streptococcus Pneumococcal Vaccines Sales YoY (2017-2028) & (K Units)
Figure 22. Europe Polyvalent Streptococcus Pneumococcal Vaccines Revenue YoY (2017-2028) & (US$ Million)
Figure 23. Asia-Pacific Polyvalent Streptococcus Pneumococcal Vaccines Sales YoY (2017-2028) & (K Units)
Figure 24. Asia-Pacific Polyvalent Streptococcus Pneumococcal Vaccines Revenue YoY (2017-2028) & (US$ Million)
Figure 25. Latin America Polyvalent Streptococcus Pneumococcal Vaccines Sales YoY (2017-2028) & (K Units)
Figure 26. Latin America Polyvalent Streptococcus Pneumococcal Vaccines Revenue YoY (2017-2028) & (US$ Million)
Figure 27. Middle East & Africa Polyvalent Streptococcus Pneumococcal Vaccines Sales YoY (2017-2028) & (K Units)
Figure 28. Middle East & Africa Polyvalent Streptococcus Pneumococcal Vaccines Revenue YoY (2017-2028) & (US$ Million)
Figure 29. The Polyvalent Streptococcus Pneumococcal Vaccines Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2021
Figure 30. The Top 5 and 10 Largest Manufacturers of Polyvalent Streptococcus Pneumococcal Vaccines in the World: Market Share by Polyvalent Streptococcus Pneumococcal Vaccines Revenue in 2021
Figure 31. Global Polyvalent Streptococcus Pneumococcal Vaccines Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2017 VS 2021
Figure 32. Global Polyvalent Streptococcus Pneumococcal Vaccines Sales Market Share by Type (2017-2028)
Figure 33. Global Polyvalent Streptococcus Pneumococcal Vaccines Revenue Market Share by Type (2017-2028)
Figure 34. Global Polyvalent Streptococcus Pneumococcal Vaccines Sales Market Share by Application (2017-2028)
Figure 35. Global Polyvalent Streptococcus Pneumococcal Vaccines Revenue Market Share by Application (2017-2028)
Figure 36. North America Polyvalent Streptococcus Pneumococcal Vaccines Sales Market Share by Type (2017-2028)
Figure 37. North America Polyvalent Streptococcus Pneumococcal Vaccines Revenue Market Share by Type (2017-2028)
Figure 38. North America Polyvalent Streptococcus Pneumococcal Vaccines Sales Market Share by Application (2017-2028)
Figure 39. North America Polyvalent Streptococcus Pneumococcal Vaccines Revenue Market Share by Application (2017-2028)
Figure 40. North America Polyvalent Streptococcus Pneumococcal Vaccines Sales Share by Country (2017-2028)
Figure 41. North America Polyvalent Streptococcus Pneumococcal Vaccines Revenue Share by Country (2017-2028)
Figure 42. United States Polyvalent Streptococcus Pneumococcal Vaccines Revenue (2017-2028) & (US$ Million)
Figure 43. Canada Polyvalent Streptococcus Pneumococcal Vaccines Revenue (2017-2028) & (US$ Million)
Figure 44. Europe Polyvalent Streptococcus Pneumococcal Vaccines Sales Market Share by Type (2017-2028)
Figure 45. Europe Polyvalent Streptococcus Pneumococcal Vaccines Revenue Market Share by Type (2017-2028)
Figure 46. Europe Polyvalent Streptococcus Pneumococcal Vaccines Sales Market Share by Application (2017-2028)
Figure 47. Europe Polyvalent Streptococcus Pneumococcal Vaccines Revenue Market Share by Application (2017-2028)
Figure 48. Europe Polyvalent Streptococcus Pneumococcal Vaccines Sales Share by Country (2017-2028)
Figure 49. Europe Polyvalent Streptococcus Pneumococcal Vaccines Revenue Share by Country (2017-2028)
Figure 50. Germany Polyvalent Streptococcus Pneumococcal Vaccines Revenue (2017-2028) & (US$ Million)
Figure 51. France Polyvalent Streptococcus Pneumococcal Vaccines Revenue (2017-2028) & (US$ Million)
Figure 52. U.K. Polyvalent Streptococcus Pneumococcal Vaccines Revenue (2017-2028) & (US$ Million)
Figure 53. Italy Polyvalent Streptococcus Pneumococcal Vaccines Revenue (2017-2028) & (US$ Million)
Figure 54. Russia Polyvalent Streptococcus Pneumococcal Vaccines Revenue (2017-2028) & (US$ Million)
Figure 55. Asia Pacific Polyvalent Streptococcus Pneumococcal Vaccines Sales Market Share by Type (2017-2028)
Figure 56. Asia Pacific Polyvalent Streptococcus Pneumococcal Vaccines Revenue Market Share by Type (2017-2028)
Figure 57. Asia Pacific Polyvalent Streptococcus Pneumococcal Vaccines Sales Market Share by Application (2017-2028)
Figure 58. Asia Pacific Polyvalent Streptococcus Pneumococcal Vaccines Revenue Market Share by Application (2017-2028)
Figure 59. Asia Pacific Polyvalent Streptococcus Pneumococcal Vaccines Sales Share by Region (2017-2028)
Figure 60. Asia Pacific Polyvalent Streptococcus Pneumococcal Vaccines Revenue Share by Region (2017-2028)
Figure 61. China Polyvalent Streptococcus Pneumococcal Vaccines Revenue (2017-2028) & (US$ Million)
Figure 62. Japan Polyvalent Streptococcus Pneumococcal Vaccines Revenue (2017-2028) & (US$ Million)
Figure 63. South Korea Polyvalent Streptococcus Pneumococcal Vaccines Revenue (2017-2028) & (US$ Million)
Figure 64. India Polyvalent Streptococcus Pneumococcal Vaccines Revenue (2017-2028) & (US$ Million)
Figure 65. Australia Polyvalent Streptococcus Pneumococcal Vaccines Revenue (2017-2028) & (US$ Million)
Figure 66. China Taiwan Polyvalent Streptococcus Pneumococcal Vaccines Revenue (2017-2028) & (US$ Million)
Figure 67. Indonesia Polyvalent Streptococcus Pneumococcal Vaccines Revenue (2017-2028) & (US$ Million)
Figure 68. Thailand Polyvalent Streptococcus Pneumococcal Vaccines Revenue (2017-2028) & (US$ Million)
Figure 69. Malaysia Polyvalent Streptococcus Pneumococcal Vaccines Revenue (2017-2028) & (US$ Million)
Figure 70. Latin America Polyvalent Streptococcus Pneumococcal Vaccines Sales Market Share by Type (2017-2028)
Figure 71. Latin America Polyvalent Streptococcus Pneumococcal Vaccines Revenue Market Share by Type (2017-2028)
Figure 72. Latin America Polyvalent Streptococcus Pneumococcal Vaccines Sales Market Share by Application (2017-2028)
Figure 73. Latin America Polyvalent Streptococcus Pneumococcal Vaccines Revenue Market Share by Application (2017-2028)
Figure 74. Latin America Polyvalent Streptococcus Pneumococcal Vaccines Sales Share by Country (2017-2028)
Figure 75. Latin America Polyvalent Streptococcus Pneumococcal Vaccines Revenue Share by Country (2017-2028)
Figure 76. Mexico Polyvalent Streptococcus Pneumococcal Vaccines Revenue (2017-2028) & (US$ Million)
Figure 77. Brazil Polyvalent Streptococcus Pneumococcal Vaccines Revenue (2017-2028) & (US$ Million)
Figure 78. Argentina Polyvalent Streptococcus Pneumococcal Vaccines Revenue (2017-2028) & (US$ Million)
Figure 79. Middle East and Africa Polyvalent Streptococcus Pneumococcal Vaccines Sales Market Share by Type (2017-2028)
Figure 80. Middle East and Africa Polyvalent Streptococcus Pneumococcal Vaccines Revenue Market Share by Type (2017-2028)
Figure 81. Middle East and Africa Polyvalent Streptococcus Pneumococcal Vaccines Sales Market Share by Application (2017-2028)
Figure 82. Middle East and Africa Polyvalent Streptococcus Pneumococcal Vaccines Revenue Market Share by Application (2017-2028)
Figure 83. Middle East and Africa Polyvalent Streptococcus Pneumococcal Vaccines Sales Share by Country (2017-2028)
Figure 84. Middle East and Africa Polyvalent Streptococcus Pneumococcal Vaccines Revenue Share by Country (2017-2028)
Figure 85. Turkey Polyvalent Streptococcus Pneumococcal Vaccines Revenue (2017-2028) & (US$ Million)
Figure 86. Saudi Arabia Polyvalent Streptococcus Pneumococcal Vaccines Revenue (2017-2028) & (US$ Million)
Figure 87. UAE Polyvalent Streptococcus Pneumococcal Vaccines Revenue (2017-2028) & (US$ Million)
Figure 88. Polyvalent Streptococcus Pneumococcal Vaccines Value Chain
Figure 89. Polyvalent Streptococcus Pneumococcal Vaccines Production Process
Figure 90. Channels of Distribution
Figure 91. Distributors Profiles
Figure 92. Bottom-up and Top-down Approaches for This Report
Figure 93. Data Triangulation
Figure 94. Key Executives Interviewed

---